MetLife Investment Management’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $264K | Buy |
19,749
+1,651
| +9% | +$22K | ﹤0.01% | 2031 |
|
|
2025
Q1 | $184K | Hold |
18,098
| – | – | ﹤0.01% | 2243 |
|
|
2024
Q4 | $286K | Buy |
18,098
+1,027
| +6% | +$16.3K | ﹤0.01% | 2102 |
|
|
2024
Q3 | $991K | Hold |
17,071
| – | – | 0.01% | 1392 |
|
|
2024
Q2 | $780K | Buy |
17,071
+3,928
| +30% | +$180K | ﹤0.01% | 1483 |
|
|
2024
Q1 | $870K | Buy |
13,143
+1,258
| +11% | +$83.3K | 0.01% | 1377 |
|
|
2023
Q4 | $473K | Hold |
11,885
| – | – | ﹤0.01% | 1720 |
|
|
2023
Q3 | $379K | Hold |
11,885
| – | – | ﹤0.01% | 1799 |
|
|
2023
Q2 | $478K | Buy |
11,885
+1,788
| +18% | +$71.8K | ﹤0.01% | 1718 |
|
|
2023
Q1 | $431K | Hold |
10,097
| – | – | ﹤0.01% | 1733 |
|
|
2022
Q4 | $485K | Buy |
10,097
+1,642
| +19% | +$78.8K | ﹤0.01% | 1663 |
|
|
2022
Q3 | $318K | Hold |
8,455
| – | – | ﹤0.01% | 1970 |
|
|
2022
Q2 | $234K | Hold |
8,455
| – | – | ﹤0.01% | 2206 |
|
|
2022
Q1 | $460K | Buy |
8,455
+2,999
| +55% | +$163K | ﹤0.01% | 1823 |
|
|
2021
Q4 | $319K | Hold |
5,456
| – | – | ﹤0.01% | 1776 |
|
|
2021
Q3 | $216K | Hold |
5,456
| – | – | ﹤0.01% | 2043 |
|
|
2021
Q2 | $232K | Hold |
5,456
| – | – | ﹤0.01% | 2065 |
|
|
2021
Q1 | $336K | Hold |
5,456
| – | – | ﹤0.01% | 1748 |
|
|
2020
Q4 | $385K | Buy |
5,456
+1,646
| +43% | +$116K | ﹤0.01% | 1607 |
|
|
2020
Q3 | $147K | Hold |
3,810
| – | – | ﹤0.01% | 2036 |
|
|
2020
Q2 | $143K | Buy |
+3,810
| New | +$143K | ﹤0.01% | 2079 |
|